To Better Days

To Better Days (formerly Horopito Limited) is a UK-based consumer healthcare company founded in 2017 that developed patented transdermal active patches for the drug-free management of chronic pain, joint and muscle discomfort, and migraines. The company's patches utilize a unique, patented combination of Vitamin D3 (cholecalciferol) and dextrose (glucose) to target nociceptors (pain receptors) and suppress hyperactivity in transient receptor potential vanilloid 1 (TRPV1) receptors. Although the company demonstrated safety and tolerability in clinical trials, it announced the closure of its direct-to-consumer operations in October 2022 due to a lack of funding. Legally, the corporate entity remains active under UK Companies House.